Alx Oncology Holdings (ALXO) Other Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings has reported Other Accumulated Expenses for 8 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 4535.42% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 4535.42% YoY) and the FY2025 annual result came in at $2.3 million, up 1459.06% from the prior year.
• Other Accumulated Expenses declined to $2.2 million in Q1 2026 per ALXO's latest filing, from $2.3 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.5 million in Q3 2025 and troughed at $40000.0 in Q2 2025.
• A 5-year average of $1.2 million and a median of $892000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses tumbled 93.24% in 2024, then jumped 4535.42% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $2.0 million in 2022, then rose by 7.56% to $2.2 million in 2023, then sank by 93.24% to $149000.0 in 2024, then soared by 1459.06% to $2.3 million in 2025, then decreased by 4.22% to $2.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.2 million, $2.3 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.